Bradley Merrill Thompson Quoted in “Health Tech Attorney: MEDTECH Act Won’t Offer Oversight Clarity or Promote Innovation”

Bloomberg BNA

Bradley Merrill Thompson, Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA, in “Health Tech Attorney: MEDTECH Act Won't Offer Oversight Clarity or Promote Innovation,” by Alex Ruoff.

Following is an excerpt:

Proponents of the MEDTECH Act have said that health IT companies want regulatory clarity in the form of legislation that specifies the FDA's role in regulating health software.

Health-care attorney Bradley Merrill Thompson, with Epstein Becker & Green PC, in Washington, who serves as regulatory counsel for the CDS Coalition, a trade association of software developers, said Dec. 10 that the bill “is a step forward” in offering that clarity.